Bernstein Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $110

Futu News09:32 · Ratings

Morgan Stanley Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $123

Futu News09:32 · Ratings

Bernstein Keeps Their Hold Rating on Merck & Company (MRK)

TipRanks08:59 · Ratings

Merck Decides To End Favezelimab Clinical Development Program, And Stop Enrollment In Phase 3 KEYFORM-008 Trial

Benzinga05:33

Express News | Merck & Co Inc - Patients in Keyform-008 Trial May Continue Therapy Until Study Completion

Breakings05:30

Express News | Merck & Co Inc - Discontinues Clinical Development Programs for Vibostolimab and Favezelimab

Breakings05:30